Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK exec caught off-guard by China graft charges: sources

Thu, 15th May 2014 09:14

By Adam Jourdan and Kazunori Takada

SHANGHAI, May 15 (Reuters) - GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be chargedwith leading a network of corruption in China's pharmaceuticalindustry, two sources with ties to the businessman and knowledgeof the investigation said.

The allegations against the Briton, who as GSK's China headwas the firm's legal representative in the country, are the mostserious charges ever laid against a foreign national forcorporate corruption in China, lawyers said.

Police said they had charged Reilly and two Chinesecolleagues with multiple offences on Wednesday, after a 10-monthprobe found the firm made billions of yuan from schemes to bribedoctors and hospitals.

"The fact that Mark's name was on the list of people chargedwas definitely a surprise," said a source with direct knowledgeof the investigation. The source declined to be named because ofthe sensitivity of the case.

Police findings are usually upheld in Chinese courts,meaning Reilly and the other executives could face decades injail.

GSK did not respond to requests for comment on Thursday.

Britain's biggest drugmaker said in a statement on Wednesdaythat the allegations were "deeply concerning" and it hoped to"reach a resolution" that would enable it to continue to operatein China, a key growth market for Western pharmaceutical giants.

Reilly, a scientist and accountant who has been with GSK forover two decades, briefly left China after the scandal broke inJuly last year. He voluntarily returned to assist authoritieswith the probe, with insiders saying the understanding was thiswould shield him from charges.

"I've had regular contact with Mark over the past fewmonths. I would think that this state of affairs is a surpriseto him. I don't think he is prepared, or thought that he couldbe culpable," an industry executive in China who has personalties to Reilly said.

Attempts to reach Reilly were unsuccessful.

NEXT STEPS

The last major corruption scandal to hit a foreign companyin China involved miner Rio Tinto in 2009,which resulted in four executives including a Chinese-bornAustralian being jailed for between seven and 14 years.

Reilly and two Chinese executives, Zhang Guowei and ZhaoHongyan, are charged with corporate bribery, bribingnon-government officials and bribing business units.

Officials gave no specific details on the amount of bribespaid or how much the company had illegally earned, althoughpreviously they accused the firm of funnelling up to 3 billionyuan ($482 million) to travel agencies to facilitate bribes todoctors and officials.

According to normal process, Reilly should have beendetained as soon as authorities laid charges against him.

Police could not be reached for comment and the Britishconsulate declined to comment on Reilly's whereabouts. Theindustry executive said he believed the Briton was still inShanghai.

Reilly had likely been barred from leaving China after hisreturn to help with the investigation, lawyers said.

WAKE-UP CALL

The prosecution will now examine the case before passing itto the courts, which could take as little as a month or muchlonger if further investigation is required, lawyers said.

GSK is the most prominent of a number of graft probes thathave been launched against global drug firms since last year,and authorities are unlikely to risk the investigation beingoverturned in the courts.

"For a sensitive and closely followed case like this, thepolice and prosecutors will have consulted with each otheralready," said Leon Liu, Shanghai-based partner at law firm MWEChina.

Chinese officials visited other international drugmakersincluding Novartis AG, AstraZeneca Plc, SanofiSA, Eli Lilly & C o and Bayer AG last year as part of a broad investigation into the sector,which is rife with bribery between sales staff and doctors.

Legal experts said the GSK case was a wake-up call toforeign companies that thought their top expatriate executiveswere immune from criminal charges as authorities step up acrackdown on corruption ordered by President Xi Jinping.

"There's a notion that only people of Chinese nationalityare going to go to jail here," said Steven Dickinson,Qingdao-based partner with law firm Harris Moure.

"People always say they'll never put a Briton or an Americanin jail. But they will, and this is just that example." (Additional reporting by John Ruwitch in SHANGHAI; Editing byStephen Coates)

More News
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.